Therapeutic options in the management of metastatic breast cancer

Michaela J. Higgins, Antonio C Wolff

Research output: Contribution to journalArticle

Abstract

Breast cancer is the second leading cause of cancer-related death in women in the United States, and for nearly all with metastatic disease at presentation or relapse it will be incurable. The goals of therapy are to optimize quality of life and, if possible, prolong time to progression of disease and death. For a select group of patients an aggressive surgical approach may be considered. Initial palliation with endocrine therapy should be the primary consideration for patients with metastatic hormone receptor-positive tumors. Cytotoxic chemotherapy is appropriate for those with hormone-refractory disease, rapidly progressive visceral disease, or early relapse after adjuvant therapy. If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible. Consequently, accurate determination of the status of these predictive markers in tissue (possibly from a recurrence site) is key. Other novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)614-623
Number of pages10
JournalOncology
Volume22
Issue number6
StatePublished - May 2008

Fingerprint

Breast Neoplasms
Recurrence
Hormones
Therapeutics
Drug Therapy
Neoplasms
Disease Progression
Quality of Life
lapatinib
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic options in the management of metastatic breast cancer. / Higgins, Michaela J.; Wolff, Antonio C.

In: Oncology, Vol. 22, No. 6, 05.2008, p. 614-623.

Research output: Contribution to journalArticle

Higgins, Michaela J. ; Wolff, Antonio C. / Therapeutic options in the management of metastatic breast cancer. In: Oncology. 2008 ; Vol. 22, No. 6. pp. 614-623.
@article{ad2057d1a1cb4ddb8d6e27e8f1a774f0,
title = "Therapeutic options in the management of metastatic breast cancer",
abstract = "Breast cancer is the second leading cause of cancer-related death in women in the United States, and for nearly all with metastatic disease at presentation or relapse it will be incurable. The goals of therapy are to optimize quality of life and, if possible, prolong time to progression of disease and death. For a select group of patients an aggressive surgical approach may be considered. Initial palliation with endocrine therapy should be the primary consideration for patients with metastatic hormone receptor-positive tumors. Cytotoxic chemotherapy is appropriate for those with hormone-refractory disease, rapidly progressive visceral disease, or early relapse after adjuvant therapy. If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible. Consequently, accurate determination of the status of these predictive markers in tissue (possibly from a recurrence site) is key. Other novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer.",
author = "Higgins, {Michaela J.} and Wolff, {Antonio C}",
year = "2008",
month = "5",
language = "English (US)",
volume = "22",
pages = "614--623",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - Therapeutic options in the management of metastatic breast cancer

AU - Higgins, Michaela J.

AU - Wolff, Antonio C

PY - 2008/5

Y1 - 2008/5

N2 - Breast cancer is the second leading cause of cancer-related death in women in the United States, and for nearly all with metastatic disease at presentation or relapse it will be incurable. The goals of therapy are to optimize quality of life and, if possible, prolong time to progression of disease and death. For a select group of patients an aggressive surgical approach may be considered. Initial palliation with endocrine therapy should be the primary consideration for patients with metastatic hormone receptor-positive tumors. Cytotoxic chemotherapy is appropriate for those with hormone-refractory disease, rapidly progressive visceral disease, or early relapse after adjuvant therapy. If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible. Consequently, accurate determination of the status of these predictive markers in tissue (possibly from a recurrence site) is key. Other novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer.

AB - Breast cancer is the second leading cause of cancer-related death in women in the United States, and for nearly all with metastatic disease at presentation or relapse it will be incurable. The goals of therapy are to optimize quality of life and, if possible, prolong time to progression of disease and death. For a select group of patients an aggressive surgical approach may be considered. Initial palliation with endocrine therapy should be the primary consideration for patients with metastatic hormone receptor-positive tumors. Cytotoxic chemotherapy is appropriate for those with hormone-refractory disease, rapidly progressive visceral disease, or early relapse after adjuvant therapy. If a tumor overexpresses HER2, targeted treatment with trastuzumab (Herceptin) or lapatinib (Tykerb) is possible. Consequently, accurate determination of the status of these predictive markers in tissue (possibly from a recurrence site) is key. Other novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=49149112250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149112250&partnerID=8YFLogxK

M3 - Article

C2 - 18561551

AN - SCOPUS:49149112250

VL - 22

SP - 614

EP - 623

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 6

ER -